Showing results (91-100 of 156) with videos related to

Sort By:
Pageof 16
Molecules (Basel, Switzerland)|November 13, 2025
From Triads to Tools: A Comprehensive Review of the Expanding Roles of G-Triplex StructuresMitchell W Myhre, Malay Kumar Das, Elizabeth P Williams, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|April 24, 2020
ELLIPTA Versus DISKUS plus HandiHaler in COPD: A Randomized, Open-Label, Crossover Study in a Clinical Trial SettingEdward M Kerwin, Selwyn Spangenthal, Michael Zvarich, et al.
Clinical Drug Investigation|June 5, 2021
Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA TrialsChristy Cappelletti, Andrea Maes, Kimberly Rossman, et al.
European Journal of Pharmacology|June 25, 2008
Cytoprotection of human endothelial cells from menadione cytotoxicity by caffeic acid phenethyl ester: the role of heme oxygenase-1Xinyu Wang, Salomon Stavchansky, Baiteng Zhao, et al.
Molecules (Basel, Switzerland)|September 28, 2024
Calcium-Dependent Chemiluminescence Catalyzed by a Truncated c-MYC Promoter G-Triplex DNAMalay Kumar Das, Elizabeth P Williams, Mitchell W Myhre, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 9, 2020
Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow® CSJudith J Stephenson, Carole Dembek, Amanda Caldwell-Tarr, et al.
Biochemistry|September 9, 1998
NMR-Based model of a telomerase-inhibiting compound bound to G-quadruplex DNAO Y Fedoroff, M Salazar, H Han, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|November 21, 2018
Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety StudyEdward M Kerwin, James F Donohue, Gary T Ferguson, et al.
Clinical Therapeutics|November 29, 2007
Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trialHarold S Nelson, Nicholas J Gross, Bernard Levine, et al.
Respiratory Medicine|January 29, 2013
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPDEdward M Kerwin, Catherine Scott-Wilson, Lisa Sanford, et al.
Pageof 16